Martin Frotscher

发表

Synthesis and Evaluation of Azole‐Substituted Tetrahydronaphthalenes as Inhibitors of P450 arom, P450 17, and P450 TxA2

R. Hartmann, M. Frotscher, G. Grün, 1996, Archiv der Pharmazie.

Development of potential preclinical candidates with promising in vitro ADME profile for the inhibition of type 1 and type 2 17β-Hydroxysteroid dehydrogenases: Design, synthesis, and biological evaluation.

R. Hartmann, M. Hamed, Mohamed Salah, 2019, European journal of medicinal chemistry.

Inhibitors of 17β-hydroxysteroid dehydrogenase type 1, 2 and 14: Structures, biological activities and future challenges

Mohamed Salah, Ahmed S. Abdelsamie, M. Frotscher, 2019, Molecular and Cellular Endocrinology.

Synthesis and Biological Evaluation of Phenyl Substituted 1H‐1,2,4‐Triazoles as Non‐Steroidal Inhibitors of 17β‐Hydroxysteroid Dehydrogenase Type 2

R. Hartmann, M. Frotscher, S. Marchais-Oberwinkler, 2012, Archiv der Pharmazie.

17β-Hydroxysteroid dehydrogenases (17β-HSDs) as therapeutic targets: Protein structures, functions, and recent progress in inhibitor development

M. Negri, R. Hartmann, J. Adamski, 2011, The Journal of Steroid Biochemistry and Molecular Biology.

Selective inhibition of 17β-hydroxysteroid dehydrogenase type 1 (17βHSD1) reduces estrogen responsive cell growth of T47-D breast cancer cells

R. Hartmann, Emmanuel Bey, S. Marchais-Oberwinkler, 2009, The Journal of Steroid Biochemistry and Molecular Biology.

Targeted Endocrine Therapy: Design, Synthesis, and Proof-of-Principle of 17β-Hydroxysteroid Dehydrogenase Type 2 Inhibitors in Bone Fracture Healing.

R. Hartmann, M. Menger, T. Pohlemann, 2019, Journal of medicinal chemistry.

Treatment of estrogen-dependent diseases: Design, synthesis and profiling of a selective 17β-HSD1 inhibitor with sub-nanomolar IC50 for a proof-of-principle study.

M. Menger, M. Laschke, Mohamed Salah, 2017, European journal of medicinal chemistry.

Structural Basis for Species Specific Inhibition of 17β-Hydroxysteroid Dehydrogenase Type 1 (17β-HSD1): Computational Study and Biological Validation

M. Negri, M. Frotscher, T. Klein, 2011, PloS one.

Dual Targeting of Steroid Sulfatase and 17β-Hydroxysteroid Dehydrogenase Type 1 by a Novel Drug-Prodrug Approach: A Potential Therapeutic Option for the Treatment of Endometriosis.

Mohamed Salah, Ahmed S. Abdelsamie, M. Frotscher, 2022, Journal of medicinal chemistry.

Development of a biological screening system for the evaluation of highly active and selective 17β-HSD1-inhibitors as potential therapeutic agents

R. Hartmann, M. Frotscher, S. Marchais-Oberwinkler, 2009, Molecular and Cellular Endocrinology.

Design, synthesis, biological evaluation and pharmacokinetics of bis(hydroxyphenyl) substituted azoles, thiophenes, benzenes, and aza-benzenes as potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1).

M. Negri, R. Hartmann, M. Frotscher, 2008, Journal of medicinal chemistry.

Design, synthesis and biological evaluation of bis(hydroxyphenyl) azoles as potent and selective non-steroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases.

R. Hartmann, M. Frotscher, Emmanuel Bey, 2008, Bioorganic & medicinal chemistry.

Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases.

R. Hartmann, C. Scherer, M. Frotscher, 2008, Journal of medicinal chemistry.

Bicyclic Substituted Hydroxyphenylmethanone Type Inhibitors of 17 β‐Hydroxysteroid Dehydrogenase Type 1 (17 β‐HSD1): The Role of the Bicyclic Moiety

R. Hartmann, M. Frotscher, S. Marchais-Oberwinkler, 2011, ChemMedChem.

Novel estrone mimetics with high 17beta-HSD1 inhibitory activity.

M. Negri, R. Hartmann, M. Frotscher, 2010, Bioorganic & medicinal chemistry.

New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitory activity and selectivity.

M. Negri, R. Hartmann, M. Frotscher, 2009, Journal of medicinal chemistry.

Structure–activity study in the class of 6-(3′-hydroxyphenyl)naphthalenes leading to an optimization of a pharmacophore model for 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) inhibitors

R. Hartmann, M. Frotscher, S. Marchais-Oberwinkler, 2009, Molecular and Cellular Endocrinology.

The role of the heterocycle in bis(hydroxyphenyl)triazoles for inhibition of 17β-Hydroxysteroid Dehydrogenase (17β-HSD) type 1 and type 2

R. Hartmann, M. Frotscher, Emmanuel Bey, 2009, Molecular and Cellular Endocrinology.

Substituted 6-phenyl-2-naphthols. Potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1): design, synthesis, biological evaluation, and pharmacokinetics.

R. Hartmann, M. Frotscher, Emmanuel Bey, 2008, Journal of medicinal chemistry.

Lead optimization of 17β-HSD1 inhibitors of the (hydroxyphenyl)naphthol sulfonamide type for the treatment of endometriosis.

R. Hartmann, A. Einspanier, M. Frotscher, 2012, Journal of medicinal chemistry.

First Dual Inhibitors of Steroid Sulfatase (STS) and 17β-Hydroxysteroid Dehydrogenase Type 1 (17β-HSD1): Designed Multiple Ligands as Novel Potential Therapeutics for Estrogen-Dependent Diseases.

Mohamed Salah, Ahmed S. Abdelsamie, M. Frotscher, 2017, Journal of medicinal chemistry.